A Human Toxoplasma Gondii Vaccine

Period of Performance: 08/31/2016 - 08/30/2018

$439K

Phase 1 SBIR

Recipient Firm

Prommune, Inc.
OMAHA, NE 68137
Principal Investigator

Abstract

To apply a novel technology platform to the development of a Toxoplasma gondii vaccine.